Generex Biotechnology (OTO:GNBT) came out strong at the opening of trading on January 26, outpacing most other peers in the directory of approximately 200 stocks we track in the cannabis industry with an early advance of 28.67%. After closing the previous session at $0.015, shares of GNBT opened this morning at $0.015 and are currently trading at $0.0193. So far, about 3.49 million shares have changed hands, compared to an average 30-day volume of 3.13 million for Generex Biotechnology. Shares moved as high at $0.02 and as low as $0.0145 in today’s early action.
The share appreciation gives the company a market capitalization of $13.55 million based upon 903.33 million shares outstanding.
In the past 52 weeks, shares of Generex Biotechnology have traded as low as $0.002 and as high as $0.015. Technical traders will take note that at $0.0193, shares of GNBT are trading above their 50-day moving average (MA) at $0.005 and above their 200-day MA at above $0.006. Technical analysts pay close attention to these key moving averages because they often serve as technical support and resistance levels and because a move above them is typically regarded as bullish.
Who is $GNBT?
Generex Biotechnology Corp is engaged in the research and development of drug delivery systems and technologies. The company is led by its CEO Mervyn Guy Fletcher from its headquarters in Toronto, ON.
For more information on GNBT and other companies focused on the expanding legal cannabis and medical marijuana industries or to considered for contributing content, visit PotNetwork.com today.
All data provided by QuoteMedia and was accurate as of 9:30AM ET.
PotNetwork.com is a leading publisher of market news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the legal cannabis and medical marijuana markets. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts interested in all segments, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications and market exposure. A complete disclaimer can be viewed here.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of PotNetwork.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://potnetwork.com/legal-disclaimer/.